Pristiq Tablet, Extended Release
Product Images NDC 0008-1211

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pristiq (NDC 0008-1211). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Wyeth Pharmaceuticals Llc, A Subsidiary Of Pfizer Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Pristiq 01)

Chemical structure diagram of the active ingredient desvenlafaxine succinate, showing its molecular components and functional groups including hydroxyl, amine, cyclohexane ring, succinate, and water of hydration.*

FDA Label Image

Figure 1 (Pristiq 02)

A forest plot chart illustrating the geometric mean ratio (90% confidence interval) of Cmax and AUC pharmacokinetic parameters for Pristiq Extended-Release (desvenlafaxine succinate) across different groups. Groups include stages of renal impairment (mild to ESRD), hepatic impairment (mild to severe), and population subgroups by gender and age. The x-axis represents change relative to reference values.*

FDA Label Image

Figure 2 (Pristiq 03)

A horizontal bar plot showing the geometric mean ratio with 90% confidence intervals for pharmacokinetic changes in Cmax and AUC of Pristiq Extended-Release tablets when coadministered with the CYP3A4 inhibitor ketoconazole. The x-axis represents change relative to reference, ranging from 0.50 to 2.0.*

FDA Label Image

Figure 3 (Pristiq 04)

A chart displaying the geometric mean ratio (90% confidence interval) for pharmacokinetic parameters (Cmax, AUC, AUCinf) comparing Pristiq extended-release tablets at various strengths (50 mg, 100 mg, 400 mg) with interacting drugs desipramine, midazolam, tamoxifen, and aripiprazole. The chart shows the change relative to reference for these drug interactions, categorized by CYP2D6, CYP3A4, and combined CYP2D6 & CYP3A4 substrates.*

FDA Label Image

Figure 4 (Pristiq 05)

A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. The graph compares two groups: one treated with PRISTIQ 50 mg (solid blue line) and the other with placebo (dashed red line). The placebo group shows a higher relapse proportion compared to the PRISTIQ 50 mg group throughout the 180-day period.*

FDA Label Image

Figure 5 (Pristiq 06)

A line chart depicting the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Pristiq Extended-Release (blue solid line) and Placebo (red dashed line). The chart shows a lower relapse rate over time for Pristiq compared to Placebo.*

FDA Label Image

Logo (Pristiq 07)

FDA Label Image

Logo (Pristiq 08)

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack Carton)

Multiple peel-off labels for Pristiq Extended-Release Tablets 50 mg by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary. Each label displays the proprietary name, generic name desvenlafaxine, strength of 50 mg*, a note referencing 76 mg desvenlafaxine succinate equivalence, barcode, NDC 0008-1211-50, lot, expiration, and manufacturing origin in Singapore.*

FDA Label Image

Principal Display Panel (50 mg Tablet Blister Pack)

Box packaging label for Pristiq (desvenlafaxine) Extended-Release Tablets, 50 mg strength. The label shows the Pfizer logo and states the tablets are oral extended-release form, with a count of 100 tablets per package. It includes storage instructions, dispensing information, and notes the product is distributed by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary, and made in Singapore.*

FDA Label Image

Principal Display Panel (50 mg Tablet Bottle Label)

Label for Pristiq (desvenlafaxine) Extended-Release Tablets, 50 mg strength, oral tablet form, manufactured by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary. The label indicates a 30-tablet unit of use, includes storage instructions, and displays Pfizer branding along with a barcode and product codes.*

FDA Label Image

Principal Display Panel (100 mg Tablet Blister Pack Carton)

Label for Pristiq (desvenlafaxine) Extended-Release Tablets, 100 mg strength, oral dosage form. The label shows the Pfizer logo and states the package contains 30 tablets. It includes storage instructions, distributor information (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.), and notes the product is made in Singapore. The label also displays the NDC number 0008-1222-30 and indicates prescription use only.*

FDA Label Image

Principal Display Panel (100 mg Tablet Blister Pack)

Label for Pristiq Extended-Release Tablets 100 mg (desvenlafaxine), showing multiple identical labels on a sheet. Each label states the product name, strength, extended-release form, and that it contains desvenlafaxine. It includes a note that the tablets are equivalent to 152 mg desvenlafaxine succinate and are made in Singapore. The label also displays the NDC 0008-1222-50, barcode, lot, and expiration date areas, and lists Wyeth Pharmaceuticals LLC, a Pfizer subsidiary, as the labeler.*

FDA Label Image

Principal Display Panel (100 mg Tablet Bottle Label)

Pristiq Extended-Release Tablets 100 mg packaging label. The box contains 100 tablets of desvenlafaxine succinate extended-release oral tablets. The label includes the Pfizer logo and instructions that the package contains 10 Redipak blister strips of 10 tablets. It notes the product is Rx only and distributed by Wyeth Pharmaceuticals LLC, a Pfizer subsidiary, made in Singapore.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

Pristiq (desvenlafaxine) Extended-Release Tablets 25 mg label from Pfizer. The label displays storage instructions, dosage strength, and identifies the product as a 30-tablet unit of use. It states the product is Rx only and manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.